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OBJECTIVE — Toestimatethecost-effectivenessofsurgicallyinducedweightlossrelativeto
conventionaltherapyforthemanagementofrecentlydiagnosedtype2diabetesinclassI/IIobese
patients.
RESEARCH DESIGN AND METHODS — This study builds on a within-trial cost-
efﬁcacy analysis. The analysis compares the lifetime costs and quality-adjusted life-years
(QALYs) between the two intervention groups. Intervention costs were extrapolated based on
observed resource utilization during the trial. The proportion of patients in each intervention
groupwithremissionofdiabetesat2yearswasthesameasthatobservedinthetrial.Healthcare
costs for patients with type 2 diabetes and outcome variables required to derive estimates of
QALYs were sourced from published literature. A health care system perspective was adopted.
Costs and outcomes were discounted annually at 3%. Costs are presented in 2006 Australian
dollars (AUD) (currency exchange: 1 AUD  0.74 USD).
RESULTS — The mean number of years in diabetes remission over a lifetime was 11.4 for
surgical therapy patients and 2.1 for conventional therapy patients. Over the remainder of their
lifetime, surgical and conventional therapy patients lived 15.7 and 14.5 discounted QALYs,
respectively. The mean discounted lifetime costs were 98,900 AUD per surgical therapy patient
and101,400AUDperconventionaltherapypatient.Relativetoconventionaltherapy,surgically
induced weight loss was associated with a mean health care saving of 2,400 AUD and 1.2
additional QALYs per patient.
CONCLUSIONS — Surgically induced weight loss is a dominant intervention (it both saves
health care costs and generates health beneﬁts) for managing recently diagnosed type 2 diabetes
in class I/II obese patients in Australia.
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P
revious studies have concluded
that surgically induced weight loss
is a cost-effective intervention for
managing severe obesity (1,2). How-
ever, no published studies have
assessed the cost-effectiveness of surgi-
callyinducedweightlossasaninterven-
tion for managing type 2 diabetes in
obese patients.
A recent randomized controlled trial
(RCT) conﬁrmed observational evidence
(3–5) that surgically induced weight loss
leadstotheremissionoftype2diabetesin
the majority of obese patients. The 2-year
RCT, which compared diabetes-related
outcomes in 60 obese (mean BMI 37 kg/
m
2) adults with recently diagnosed (2
years) type 2 diabetes randomized to ei-
ther surgical therapy (laparoscopic ad-
justable gastric banding [LAGB]) or
conventional therapy, has previously
been reported (6).
Previously, we reported the within-
trial mean intervention costs as 13,400
AUD and 3,400 AUD per patient for sur-
gical therapy and conventional therapy,
respectively.Thecost-efﬁcacyforsurgical
therapy compared with conventional
therapy was 16,600 AUD per case of type
2 diabetes remitted (7). The key strength
of this study was the certainty of the re-
sults: the analysis was based directly on
observed trial cost and efﬁcacy data. The
key limitations of this analysis were the
short time horizon for analysis (2 years)
and the disease-speciﬁc outcome metric
(cases of type 2 diabetes remitted). De-
creasing surgical therapy costs over time
andthefuturecostburdenoftreatingtype
2 diabetes warrant analyses over a longer
time horizon. Expansion of the beneﬁt
measurement to capture quality of life
and life expectancy gains is also required
to enable comparison with other cost-
effectiveness analyses.
This study builds on the within-trial
cost-efﬁcacy analysis by extrapolating
costs and outcomes from those observed
over the 2-year trial to the lifetime of the
trial population. It aims to determine the
cost-effectiveness of surgically induced
weight loss relative to conventional ther-
apyforthemanagementoftype2diabetes
in class I and II obese patients.
RESEARCH DESIGN AND
METHODS— An incremental cost-
effectiveness analysis was undertaken,
where the net costs and effectiveness of
surgical therapy compared with con-
ventional therapy were calculated and
expressed as an incremental cost-
effectiveness ratio (ICER). Costs include
the lifetime cost of the interventions and
the health care costs to treat type 2 diabe-
tes. Effectiveness results are expressed as
the number of quality-adjusted life-years
(QALYs)gained.Analysiswasundertaken
from a health care system perspective.
The use of health care resources by gov-
ernment, private insurers, and patients is
included in the cost analysis. Outcomes
are primarily acquired by patients (rather
than government and private insurers);
therefore, QALYs are used as the unit of
measure on the beneﬁts side of the anal-
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and QALYs were estimated. Costs are re-
ported in 2006 Australian dollars (AUD).
Costs sourced from alternative years are
presented in 2006 values by applying the
relevant price deﬂators (8). The midyear
2006 currency exchange rate, according
to the XE currency Web site (9) was 1
AUD to 0.74 USD.
Modeling
Model structure. A Markov model that
is representative of the natural history of
type 2 diabetes for patients managed by
either surgical therapy or conventional
was constructed using TreeAge Pro Suite
2008 with links to Excel. Three health
statesweredeﬁned:type2diabetesremis-
sion, type 2 diabetes, and death. Health
state transitions were limited to mainte-
nance of the current health state or dete-
rioration (Fig. 1). The model cycle length
was 1 year, and half-cycle corrections
were applied. Modeling was applied from
the end of the 2-year RCT, with surgical
and conventional therapy groups enter-
ing the model with their end-of-RCT
mean age, mean BMI, diabetes status, and
accumulated RCT intervention costs (see
Table 2). The model was run until pa-
tients died or reached 99 years of age. Re-
sults of the model were generated using
Monte Carlo simulation. Mean results are
based on 20,000 random walks of the
model.
Lifetime intervention pathways. The
conventionaltherapyinterventionwasas-
sumed to be implemented for the 2-year
trial period. The surgical therapy inter-
vention was assumed to be a lifetime pro-
gramtomonitorandmaintainweightloss
and the LAGB. Patients exiting the trial in
type 2 diabetes remission (regardless of
assigned intervention) were assumed to be
monitored for maintenance of remission.
Variables within the model
Trial intervention effect. The trial in-
tervention effect (type 2 diabetes status at
end of trial) was applied as the relative
risk of remission for surgical relative to
conventional therapy patients. Uncer-
tainty around the intervention effect was
captured by assuming a normal probabil-
ity distribution around the log of the rel-
ative risk reported for the RCT (6).
Univariate probabilistic uncertainty anal-
ysis was undertaken to examine the effect
of uncertainty around the relative risk us-
ing a Monte Carlo simulation. Simulation
for 1,000 cohorts, each involving 20,000
iterations, was used to estimate the 95%
uncertaintyinterval(UI)aroundthemean
ICERandprobabilitiesofacceptablecost-
effectiveness. All patients were assumed
tohaveameandurationoftype2diabetes
of3yearsattheendofthetrial.Therefore,
beneﬁts associated with diabetes remis-
sion accumulated after the trial period
only.
Intervention costs. Surgical therapy
maintenancecostswereappliedeachyear
that surgical patients remained alive. The
frequencyofoutpatientmedicalconsulta-
tions and investigations was estimated by
surgical experts at the Centre for Obesity
ResearchandEducation,MonashUniver-
sity, who have maintained a database of
4,500 LAGB patients over 14 years.
Surgical therapy complication costs
were applied each year that surgical pa-
tients remained alive. Lifetime complica-
tion rates were estimated based on
published data (10) and consultation
with the authors to extrapolate results
over the lifetime. The cumulative proba-
bility of a complication was estimated to
be 17% every 10 years. To derive annual
costs, it was assumed that complication
rateswereindependentandconstantover
time. Resource use for surgical proce-
dures to mitigate complications was esti-
mated by trial surgeons based on the
LAGB surgery for trial patients (7) (with
adaptations to operating time, length of
admission, and prosthesis requirements
[details available on request]). Surgical
costsweresourcedfromaprivatehospital
and private medical specialists to reﬂect
private provision as is commonly prac-
ticed in Australia. LAGB prostheses were
valued based on commercial prices.
Diabetes remission–monitoring costs
were applied each year that patients were
in the type 2 diabetes remission health
state. Medication and outpatient consul-
tationresourceusewasextrapolatedfrom
thesurgicalinterventiongroupduringthe
last 6 months of the trial. Medical inves-
tigations and pathology requirements
wereestimatedbyaphysicianwithexper-
tise in diabetes management. Unless oth-
erwise speciﬁed, unit costs for all
resources were obtained from the Austra-
lian 2006 Medicare Beneﬁts Schedule
(11) and Pharmaceutical Beneﬁts Sched-
ule (12).
Treatment costs. Mean annual health
carecostsforpatientswithtype2diabetes
were sourced from the DiabCo$t study
(13), which collected self-reported medi-
cation (antidiabetes, insulin, hypoglyce-
mic, lipid lowering, and blood pressure
Figure 1—Markov model: health states and ﬁrst cycle annual transition probabilities.
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eralpractitionerconsultations,outpatient
consultations, emergency ambulance,
and emergency admissions), and in-
hospital costs from 10,600 patients from
the Australian Diabetes Supplies and Ser-
vices Register in 2001. Some costs unre-
latedtotype2diabetesarelikelyincluded
because of the study’s wide cost inclusion
criteria. It is difﬁcult to quantify this pro-
portion; thus, a worst-case scenario esti-
mateof43%,asreportedbytheAmerican
Diabetes Association, was assumed (14).
Health care costs for patients with type 2
diabetes (mean 5,000 AUD) were applied
at 100% to patients with type 2 diabetes
and 43% for patients in diabetes remis-
sion. The costs were provided disaggre-
gatedbydiabetesdurationandpatientage
and assigned based on these variables to
simulate the escalation of costs with dis-
ease duration and aging (cost for diabetes
remission based on a ﬁxed duration of
5–10 years of disease).
Utility weights. Utility-based weights
reﬂecting 1 year of quality-adjusted sur-
vival associated with type 2 diabetes sta-
tus were assigned each year patients were
alive. A mean utility weight equivalent to
0.80 (age range 51–65 years) reﬂecting
the type 2 diabetes health state was
sourced from the DiabCo$t study, which
administered the EuroQol 5-domain
(EQ-5D) questionnaire to the same pop-
ulation sample as that of the cost survey
described above (13). Utility weights
were assigned based on duration of
disease.
As a result of an absence of evidence
regarding the quality-adjusted survival
associated with remission from type 2 di-
abetes, it was assumed that these patients
have a similar quality of life to that of the
general population. A ﬁxed utility weight
for the Australian general population (age
range 51–65 years) of 0.84, also esti-
mated using the EQ-5D (15), was as-
signed to these patients.
Transition probabilities. Annual prob-
abilitiesforrelapseoftype2diabeteswere
applied to patients in the diabetes remis-
sion health state. The Swedish Obese
Study (SOS) and the Greenville Series re-
port that, for patients achieving diabetes
remission after surgically induced weight
loss, the mean duration of remission is 10
years and substantially greater than 16
years, respectively (3,5). An estimate at
the lower end of this range (13 years) is
adopted for the primary analysis and was
converted to a constant annual probabil-
ity for relapse.
Annual mortality probabilities were
applied each year that patients were alive
and were assigned based on type 2 diabe-
tes status and age. Because of an absence
of evidence regarding mortality risks for
patients in remission from type 2 diabe-
tes, this risk was assumed to be the same
as that for patients without diabetes. Age-
speciﬁc annual mortality probabilities for
patients with and without diabetes were
sourcedfroma2008studybyMaglianoet
al. (16), which combined data from a na-
tional Australian cohort study (AusDiab)
with national Australian mortality data.
All model inputs and sources are summa-
rized in Tables 1 and 2.
Uncertainty analysis
The impact of model variable uncertainty
on the ICER was tested. Values tested re-
ﬂectedworst-casescenarios(i.e.,decreas-
ing cost-effectiveness of surgical therapy)
and are described in Tables 1 and 2. The
impactofcombinationsofvariableslikely
to be related were tested, including 1)
combiningallinterventioncostsinworst-
casescenariosand2)combininginterven-
tion effect and duration of diabetes
remission in worst-case scenarios. Uncer-
tainty in modeling assumptions was also
tested, including 1) adding an additional
LAGB surgical event to the lifetime inter-
ventioncostforeachsurgicalpatient(i.e.,
reﬂecting a routine LAGB replacement),
2) applying ﬁxed health care treatment
costs and utilities associated with type 2
diabetes (i.e., excluding the effects of dis-
easedurationandage),3)applyingtype2
diabetes mortality probabilities to all pa-
tients (i.e., assuming that the mortality
probability of the population free of dia-
betesisnottransferabletopatientsintype
2 diabetes remission), and 4) introducing
a0.03%probabilityofpostoperativemor-
tality for LAGB patients (i.e., superseding
the actual zero mortality found in a trial
with a probability reported by a system-
atic review [17]). Threshold analysis was
undertaken to identify the minimum du-
ration of diabetes remission required to
deem surgical therapy cost-effective, as-
suming a willingness to pay threshold of
50,000 AUD per QALY (18).
RESULTS— Based on the assump-
tions and model parameters described,
and relative to conventional therapy pa-
tients, surgical therapy patients gained a
mean 9.4 additional years in diabetes re-
mission, 1.6 additional life-years (undis-
counted), and 1.2 discounted QALYs.
Meandiscountedcostsperpatientwere
asfollows:98,900AUDforsurgicaltherapy
and 101,400 AUD for conventional ther-
apy. The health care cost to treat type 2 di-
abetes was the overwhelming cost driver
and cost differential between the two inter-
vention groups.
Relative to conventional therapy, sur-
gically induced weight loss was a domi-
nant alternative (associated with health
care savings and health beneﬁts) for man-
aging type 2 diabetes in obese patients.
On average, surgical therapy was associ-
ated with health care savings of 2,400
AUD and an additional 1.2 discounted
QALYs per patient (95% CI dominant to
48,400 per QALY for ICER). The proba-
bility of surgical therapy being domi-
nantandcost-effectivewas57and98%,
respectively. Results are summarized in
Table 3.
Uncertainty in model values and as-
sumptions either maintained the domi-
nantstatusofsurgicaltherapyorshiftedit
into a very cost-effective status ( 7,000
AUD per QALY), with the following ex-
ceptions. Worst-case scenarios for the in-
tervention effect and the annual cost of
treating type 2 diabetes shifted the eco-
nomic status of surgical therapy from
dominant to cost-effective (39,700 AUD
and 13,400 AUD per QALY, respec-
tively). Combining the intervention effect
and duration of diabetes remission in
worst-case scenarios also shifted the eco-
nomic status of surgical therapy to cost-
effective (48,200 AUD per QALY).
Detailed uncertainty results are listed in
an online appendix (available at http://
care.diabetesjournals.org/cgi/content/full/
dc08-1749/DC1). Threshold analysis indi-
cated that surgical therapy is cost-effective
when the mean duration of remission from
type 2 diabetes is at least 2 years and dom-
inant when the mean duration of remission
is at least 10 years.
CONCLUSIONS — Discounted re-
sults from this analysis suggest that both
health gains and health care cost savings
arelikelyrealizedbysubstitutingconven-
tional therapy with surgical therapy for
obese patients presenting with recently
diagnosed type 2 diabetes. Strictly from a
cost perspective (disregarding quality of
life and life expectancy beneﬁts of diabe-
tes remission), this analysis suggests that
after 10 years the return on investment
of surgical therapy is fully recovered
through savings in health care costs to
Keating and Associates
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group.
These results underestimate the po-
tential beneﬁts of surgical therapy. First,
thisanalysiscapturesonlyonebeneﬁt:the
remission of type 2 diabetes. The surgical
intervention also facilitated signiﬁcant
and sustained weight loss (mean BMI
from 37 to 29 kg/m
2). The analysis did
not seek to capture non–diabetes-related
1)healthcarecostsavingsassociatedwith
a reduction in obesity-related morbidity
(19), 2) improvements in quality of life
attributable to weight loss after bariatric
surgery (20), or 3) survival beneﬁts of
weightlossafterbariatricsurgery(19,21).
Second, the analysis did not endeavor to
capture the substantial beneﬁts from gly-
cemic control demonstrated by surgical
patients who did not achieve type 2 dia-
betesremission.Third,wedidnotapplya
differential duration of diabetes remis-
sion to conventional therapy patients,
despite evidence that nonsurgical inter-
ventions fail to demonstrate mainte-
nance of weight loss over time (22),
whichmaycorrelatewithfasterdiabetes
relapse. Finally, no beneﬁts were ap-
plied to the trial period.
Comparison with the literature
Previousstudieshavefoundsurgicallyin-
duced weight loss to be a cost-effective
intervention for managing obesity (1,2).
This study ﬁnds surgically induced
weight loss for managing type 2 diabetes
in the obese population to be superior
from an economic perspective because it
is generates both cost savings and health
beneﬁts. The cost-saving result is consis-
tent with ﬁndings from a 2008 U.S. study
by Cremieux et al. (23), which found,
based on a third-party payer perspective
of actual patient costs, that the initial in-
vestmentinbariatricsurgerywasoffsetby
downstream health care savings after 4
years.
Resource assumptions employed by
our study differ from previous economic
evaluations of LAGB surgery. Efﬁciency
gainsinLAGBsurgerytechniquesarecap-
tured by adopting signiﬁcantly lower (ac-
tual RCT) mean operating and admission
durations. Safety gains are captured by
including (actual RCT) zero operative
mortality. We employed a more com-
prehensive approach to estimating com-
plication rates, including all serious
perioperative complications and extrapo-
lating rates over the lifetime of patients.
Optimal schedules for maintaining
weight loss are captured through a rigor-
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572 DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009ous postoperative follow-up schedule (20
consultationsintheﬁrst2yearsand4per
year thereafter per patient), as discussed
intheassociatedcost-efﬁcacyanalysis(7).
Limitations
Thetransferabilityofdiabetesremission
duration results from the Greenville Se-
ries and SOS to this RCT is uncertain—
the Greenville Series because research
suggests that the surgical technique em-
ployed, gastric bypass surgery, contrib-
utes to diabetes remission through
mechanisms independent of weight loss
(24) and the SOS study because weight
loss (the driver of type 2 diabetes remis-
sion through LAGB [6]) was poorly sus-
tained,contrarytosustainedweightloss
anticipated for the LAGB trial popula-
tion (25). Additionally, the duration of
type 2 diabetes for patients in our RCT
(all recently diagnosed) was likely sub-
stantially shorter than that of the Gre-
enville and SOS studies, which may
correlate with improved diabetes remis-
sion outcomes for our trial patients.
To simulate outcomes in the period
after the trial, we made assumptions
about the costs, diabetes relapse rate,
and mortality rate for patients in remis-
sion from diabetes. While our assump-
tions were based on the best available
data, the possibility that some were
wrong was tested by extensive uncer-
tainty analyses.
The generalizability of cost-effective-
ness results to other populations may be
limited due to different intervention effects,
complication rates, or health care costs. Re-
sults are only directly transferable to the
clinical population with class I and II obe-
sity and recently diagnosed type 2 diabetes
in Australia.
Inconclusion,theRCTdemonstrated
the health beneﬁts of substantial weight
loss for the obese patient with recently
diagnosed type 2 diabetes. The present
study shows that this beneﬁt can be
achieved with associated cost savings.
Substantial weight loss should be sought
in all such patients, and if nonsurgical
measures are unsuccessful, the option of
LAGB should be discussed.
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